Nicox launches expanded access to Sequenom’s RetnaGene tests in U.S.
Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests-RentaGene AMD and RetnaGene LR-which asses an individual’s risk for advanced age-related macular degeneration (AMD).
San Diego, CA-Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests-RentaGene AMD and RetnaGene LR-which asses an individual’s risk for advanced age-related macular degeneration (AMD).
“The RetnaGene tests allow for improved patient management, by examining the most relevant genetic markers for a more accurate prediction of advanced AMD risk,” says Jerry St. Peter, executive vice president and general manager of Nicox Inc.
The tests collect DNA specimens with an in-office buccal swab. In January 2014, Sequenom Laboratories granted Nicox exclusive promotion and marketing rights for its RetnaGene tests.
“Currently there is much debate in the medical community surrounding the best way to incorporate genetic testing for AMD into clinical practice. Expanded access to the RetnaGene tests will provide broader use and education to clinicians about this important technology,” said Quan Dong Nguyen, MD, MSc, who holds the McGaw Memorial Endowed Chair in Ophthalmology and is the inaugural director of the Truhlsen Eye Institute, University of Nebraska Medical Center.
Related: AMD genetic testing could lead to early diagnosis, better treatment
